COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
COMPASS Pathways plcNASDAQ: CMPS
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.3, compared with -$0.24 a year earlier. Trailing-twelve-month EPS (Diluted) was -$3.15.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$0.73 (+76.2%) for the fiscal year ending Dec 2026, a step up from the -33.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.3+70.0% QoQ
- Last fiscal yearDec 2025
- -$3.08-33.9% YoY
- LTMMar 2026
- -$3.15-58.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -25.0% | +5.7% | +30.7 pp |
| 1 year | -33.9% | +76.2% | +110.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (3.08) USD
- Year-over-year change
- -33.9%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.08) | -33.9% |
| FY2024 | 2024-12-31 | (2.30) | +0.9% |
| FY2023 | 2023-12-31 | (2.32) | -7.4% |
| FY2022 | 2022-12-31 | (2.16) | -20.7% |
| FY2021 | 2021-12-31 | (1.79) | — |
EPS (Diluted) vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 EPS (Diluted) of -$3.15 is the 7th highest of the 11 companies compared; the peer median is -$2.93.
- Its year-over-year change of -58.3% is the 8th highest of 10, against a peer median of -15.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $3.08 | -0.6% | -3.0% | |
| LTM Sep 2026 | $2.11 | +36.1% | — | |
| LTM Mar 2026 | -$0.92 | -16.5% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$2.6 | -15.6% | — |
| LTM Jun 2026 | -$2.84 | -1.4% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$3.02 | -48.0% | — |
| LTM Mar 2026 | -$3.15 | -58.3% | — | |
| LTM Mar 2026 | -$4.58 | -134.9% | — | |
| LTM Sep 2026 | -$12.8 | +0.8% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$21.47 | — | — |
| LTM Jun 2026 | -$28.87 | -2050.7% | — | |
| Peer median (excluding CMPS) | -$2.93 | -15.6% | -3.0% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.